Jefferson scientists show bacterial toxin slows metastatic colorectal cancer tumor growth

July 02, 2001

Researchers at Jefferson Medical College and Jefferson's Kimmel Cancer Center have found that a receptor for a bacterial toxin on the surface of metastatic colorectal cancer cells actually controls the growth of the cells. What's more, when the toxin hooks up with the receptor, metastatic colorectal cancer cell growth slows considerably. The scientists believe the receptor-toxin combination could eventually be used with chemotherapy or other agents to slow the advance of the disease.

"Cancer then becomes a chronic disease," says Scott Waldman, M.D., Ph.D., Samuel M.V. Hamilton Family Professor of Medicine and director of the Division of Clinical Pharmacology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, who, along with Giovanni Pitari, M.D., Ph.D., assistant professor of medicine at Jefferson Medical College, led the work. They report their findings July 3 in the Proceedings of the National Academy of Sciences.

Several years ago Dr. Waldman's team discovered the existence of a protein marker, GCC, on the surface of colorectal cancer cells that allows scientists to detect if cells have spread to other areas of the body and where, he says, "they don't belong." GCC can be used as a diagnostic tool to stage patients and to follow them after their surgery to see if their cancer has returned. It turns out that GCC is also a receptor for a bacterial toxin, ST, the cause of traveler's diarrhea.

"Because it's a receptor that sits on the cancer cell surface, when these cells become metastatic, they go to places where the normal tissue doesn't make this receptor," Dr. Waldman explains. "GCC - and the cancer - can be targeted using the bacterial toxin to the receptor."

As a result, GCC is particularly useful. The scientists are testing the receptor as a target for imaging agents to find where in the body metastatic cancer has gone. It also can be used therapeutically, says Dr. Waldman, by coupling cell-killing drugs to the toxin, then homing in on the cancer. GCC is a potential target at which to shoot so-called guided cellular missiles.

Drs. Pitari and Waldman, in anticipation of beginning studies to examine this ST targeting of therapeutics to GCC on colorectal tumors, decided to look at colorectal cancer cells in the laboratory to see if ST itself actually had an effect on the cells.

They were astounded to find that GCC actually regulated the growth of colorectal cancer cells, and that treating the cells with ST didn't kill cancer cells, but rather lengthened the time of the cell growth cycle, slowing the cells' growth and spread.

The researchers think they can take advantage of this "cytostatic," or cell growth-slowing action. "We may be able to use ST as a therapeutic hormone to slow down cancer growth," says Dr. Pitari. "Or we may use ST or another ligand that binds to GCC in combination with another agent to keep tumors at bay." Their next step is to continue their laboratory studies and look into new agents that may work in combination with GCC.
-end-


Thomas Jefferson University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.